News & Views - Page 40 of 53 - Telix Pharmaceuticals Limited

Cardinal Health and Telix Launch Gallium Awareness Campaign

In collaboration with Cardinal Health, Telix is pleased to announce the launch of a gallium awareness campaign with the release of an in-depth white-paper entitled: “Moving beyond the Myth”.

TLX66 Meets Study Objectives in Patients with AL Amyloidosis

Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL amyloidosis.

First Patient Dosed in Japanese Prostate Cancer Imaging Study

Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product, Illuccix®.

Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging

Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German market.

Telix at ANZSNM Annual Scientific Meeting

Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live and local.

Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses

Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.

Telix and Monrol Expand Alliance to Include Lutetium Supply

Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR products.

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced prostate cancer.

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.

Telix Pharmaceuticals Appoints Richard Valeix as EMEA President

Telix announces Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa (EMEA).